Home › Spinal Cord Injuries › NCT06840899

CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* \>18 years of age
* History of supra-sacral spinal cord injury of any mechanism
* Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock)
* Willingness to participate in drug intervention trial
* English-speaking (able to provide consent and complete questionnaires)

Exclusion Criteria:

* History of intravesical Botox
* Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms
* Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported
* Thought or mood disorder aside from depression

About the study

The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI).

Participants will take Epidiolex (purified CBD) for 90 days

What is being tested

• CBD (drug)

Sponsor: University of Wisconsin, Madison · Participants: 20 · Started: Feb 13, 2026

Contact the study team

• Maria Flory · Phone: 608-262-8652

Official record on ClinicalTrials.gov — NCT06840899

Locations in the U.S.

Conditions

• Spinal Cord Injuries
• Urinary Incontinence

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.